Evidence map›Paper›PMID 27367739›Full record

ReviewAntibiotics (Basel, Switzerland)2016

Ribosomal Antibiotics: Contemporary Challenges.

Tamar Auerbach-Nevo, David Baram, Anat Bashan, Matthew Belousoff, Elinor Breiner, Chen Davidovich, Giuseppe Cimicata, Zohar Eyal, Yehuda Halfon, Miri Krupkin and 21 more

Open access · goldAbstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Investigation of Macrolide Resistance Genotypes inPathogens (Basel, Switzerland) · 2020
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 1 institution in 1 country.

Tamar Auerbach-NevoDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. tauerba@its.jnj.com.
David BaramDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. david@smzyme.com.
Anat BashanDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. anat.bashan@weizmann.ac.il.
Matthew BelousoffDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. matthew.belousoff@monash.edu.
Elinor BreinerDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. elinor.breiner@weizmann.ac.il.
Chen DavidovichDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. Chen.Davidovich@monash.edu.
Giuseppe CimicataDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. giuseppe.cimicata@gmail.com.
Zohar EyalDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. zohar.baram@weizmann.ac.il.
Yehuda HalfonDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. Yehuda.Halfon@weizmann.ac.il.
Miri KrupkinDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. Miri.Krupkin@weizmann.ac.il.
Donna MatzovDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. Matzov.donna@weizmann.ac.il.
Markus MetzDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. markusmetz.at@gmail.com.
Mruwat RufaydaDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. Rufayda.Mruwat@weizmann.ac.il.
Moshe PeretzDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. moshe.peretz@weizmann.ac.il.
Ophir PickDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. ophir.pick@gmail.com.
Erez PyetanDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. erezpy@gmail.com.
Haim RozenbergDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. Haim.Rozenberg@weizmann.ac.il.
Moran Shalev-BenamiDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. benami.moran@gmail.com.
Itai WekselmanDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. Itai.Wekselman@weizmann.ac.il.
Raz ZarivachDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. zarivach@bgu.ac.il.
Ella ZimmermanDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. Ella.Zimmerman@weizmann.ac.il.
Nofar AssisDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. nofar.assis@gmail.com.
Joel BlochDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. joel.bloch@mol.biol.ethz.ch.
Hadar IsraeliDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. hadarisr@bgu.ac.il.
Rinat KalaoraDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. rinat.kalaora@gmail.com.
Lisha LimDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. lishaqjl@gmail.com.
Ofir Sade-FalkDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. ofir.sadefalk@gmail.com.
Tal ShapiraDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. Tal.Shapira@weizmann.ac.il.
Leena Taha-SalaimeDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. Leena.ta.salaime@gmail.com.
Hua TangDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. hua2han2003@yahoo.com.
Ada YonathDepartment of Structural Biology, Weizmann Institute, Rehovot 76100, Israel. Ada.Yonath@weizmann.ac.il.
Weizmann Institute of Science · IL

Funding

CRYSTALLOGRAPHIC STUDIES ON RIBOSOMAL PARTICLESR01GM034360 · NIGMS · WEIZMANN INSTITUTE OF SCIENCE · PI YONATH, ADA E · 1985 to 2010
$2.2M
NIGMS NIH HHS R01 GM034360
6 · The paper itself

Abstract

Most ribosomal antibiotics obstruct distinct ribosomal functions. In selected cases, in addition to paralyzing vital ribosomal tasks, some ribosomal antibiotics are involved in cellular regulation. Owing to the global rapid increase in the appearance of multi-drug resistance in pathogenic bacterial strains, and to the extremely slow progress in developing new antibiotics worldwide, it seems that, in addition to the traditional attempts at improving current antibiotics and the intensive screening for additional natural compounds, this field should undergo substantial conceptual revision. Here, we highlight several contemporary issues, including challenging the common preference of broad-range antibiotics; the marginal attention to alterations in the microbiome population resulting from antibiotics usage, and the insufficient awareness of ecological and environmental aspects of antibiotics usage. We also highlight recent advances in the identification of species-specific structural motifs that may be exploited for the design and the creation of novel, environmental friendly, degradable, antibiotic types, with a better distinction between pathogens and useful bacterial species in the microbiome. Thus, these studies are leading towards the design of "pathogen-specific antibiotics," in contrast to the current preference of broad range antibiotics, partially because it requires significant efforts in speeding up the discovery of the unique species motifs as well as the clinical pathogen identification.

Indexed as

microbiomemulti-drug resistancenovel degradable antibioticsspecies-specific antibiotics susceptibility

Identifiers

PMID27367739
PMCPMC5039520
OpenAlexW2470149719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.